Provided by Tiger Fintech (Singapore) Pte. Ltd.

DOGWOOD THERAPEUTICS INC

6.60
+2.1748.98%
Post-market: 6.920.3200+4.85%19:59 EST
Volume:25.92M
Turnover:173.77M
Market Cap:8.79M
PE:-1.03
High:8.06
Open:4.41
Low:4.04
Close:4.43
Loading ...

Dogwood Therapeutics Inc expected to post a loss of $1.41 a share - Earnings Preview

Reuters
·
24 Feb

DWTX Stock trading resumes

TIPRANKS
·
12 Feb

DWTX Stock trading halted, volatility trading pause

TIPRANKS
·
12 Feb

4 Stocks to Buy on Trump’s Turbocharged News Cycle

InvestorPlace
·
10 Feb

DWTX Stock trading resumes

TIPRANKS
·
27 Jan

DWTX Stock trading halted, volatility trading pause

TIPRANKS
·
27 Jan

Dogwood announces first patient dosed in Phase 2b trial on Halneuron

TIPRANKS
·
21 Jan

Dogwood Therapeutics Announces Patient Dosing in Phase 2B Trial Evaluating Halneuron® in Patients With Chemotherapy Induced Neuropathy (Cinp) to Commence First Quarter of 2025

THOMSON REUTERS
·
21 Jan

Dogwood Therapeutics Inc - Interim Data From Phase 2 Cinp Study Expected in 2H 2025

THOMSON REUTERS
·
21 Jan

Wall Street Set to Open Mixed Tuesday Ahead of Holiday Break

MT Newswires Live
·
24 Dec 2024

BRIEF-Dogwood Therapeutics Announces Low Dose IMC-2 Treatment

Reuters
·
18 Nov 2024

Dogwood says low-dose IMC-2 treatment reduces long-COVID fatigue

TIPRANKS
·
18 Nov 2024

Dogwood Therapeutics, Inc. Announces Low Dose Imc-2 Treatment Reduces Long-Covid Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study

THOMSON REUTERS
·
18 Nov 2024

Dogwood Therapeutics Inc - Imc-2 Shows Robust Reduction in Fatigue

THOMSON REUTERS
·
18 Nov 2024

DWTX: Phase 2 Long COVID Results Expected Soon

Zacks Small Cap Research
·
11 Nov 2024

Dogwood Therapeutics Faces Potential Asset Loss and Financial Risks Amid Sealbond Repurchase Option

TIPRANKS
·
09 Nov 2024